GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (OSTO:SPAGO) » Definitions » ROC %

Spago Nanomedical AB (OSTO:SPAGO) ROC % : -752.21% (As of Sep. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Spago Nanomedical AB ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Spago Nanomedical AB's annualized return on capital (ROC %) for the quarter that ended in Sep. 2024 was -752.21%.

As of today (2024-12-14), Spago Nanomedical AB's WACC % is 2.94%. Spago Nanomedical AB's ROC % is -103.28% (calculated using TTM income statement data). Spago Nanomedical AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Spago Nanomedical AB ROC % Historical Data

The historical data trend for Spago Nanomedical AB's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB ROC % Chart

Spago Nanomedical AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.73 -14.34 -28.37 -27.43 -56.32

Spago Nanomedical AB Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.68 -47.16 -581.81 -643.25 -752.21

Spago Nanomedical AB ROC % Calculation

Spago Nanomedical AB's annualized Return on Capital (ROC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-42.505 * ( 1 - 0% )/( (144.782 + 6.164)/ 2 )
=-42.505/75.473
=-56.32 %

where

Spago Nanomedical AB's annualized Return on Capital (ROC %) for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-36.392 * ( 1 - 0% )/( (5.562 + 4.114)/ 2 )
=-36.392/4.838
=-752.21 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Spago Nanomedical AB  (OSTO:SPAGO) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Spago Nanomedical AB's WACC % is 2.94%. Spago Nanomedical AB's ROC % is -103.28% (calculated using TTM income statement data). Spago Nanomedical AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Spago Nanomedical AB ROC % Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Spago Nanomedical AB Business Description

Traded in Other Exchanges
N/A
Address
Scheelevagen 22, Lund, SWE, SE-223 63
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through previous detection of tumors and metastases. The Tumorad products focuses on the development of a completely new form of radionuclide therapy for tumor selective radiation therapy of cancer. The company development projects are based on a platform of polymeric materials with varoious properties for precise diagnosis and treatment of life threatening and debilitating diseases.

Spago Nanomedical AB Headlines

No Headlines